- Home
- CRDF
as 07-26-2024 4:00pm EST
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").
| Founded: | 1999 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 105.1M | IPO Year: | N/A |
| Target Price: | $10.50 | AVG Volume (30 days): | 770.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.90 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.94 - $6.42 | Next Earning Date: | 08-07-2024 |
| Revenue: | $610,000 | Revenue Growth: | 54.43% |
| Revenue Growth (this year): | -18.22% | Revenue Growth (next year): | -82.96% |
Stock Insider Trading Activity of Cardiff Oncology Inc. (CRDF)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| PACE GARY W | CRDF | Director | Dec 19 '23 | Buy | $1.37 | 30,000 | $41,100.00 | 697,761 | SEC Form 4 |
| PACE GARY W | CRDF | Director | Nov 10 '23 | Buy | $0.98 | 22,950 | $22,491.00 | 667,761 | SEC Form 4 |
Latest Cardiff Oncology Inc. News
CRDF Breaking Stock News: Dive into CRDF Ticker-Specific Updates for Smart Investing
Simply Wall St.
2 days ago
Companies Like Cardiff Oncology (NASDAQ:CRDF) Are In A Position To Invest In Growth
GlobeNewswire
2 months ago
Cardiff Oncology to Present at the Jefferies Healthcare Conference
GlobeNewswire
2 months ago
Cardiff Oncology to Present at Upcoming Investor Conferences in May
Simply Wall St.
3 months ago
Cardiff Oncology First Quarter 2024 Earnings: Beats Expectations
GlobeNewswire
3 months ago
Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update
GlobeNewswire
3 months ago
Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update
GlobeNewswire
4 months ago
Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study
GlobeNewswire
5 months ago
Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024
Compare CRDF vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CRDF Cardiff Oncology Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.